Price
No data yet.
Social Signal Score
Analyst Ratings
3 analystsRevenue
$0.00-100.00%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- John Friend
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 6
- Beta
- 2.27
- Country
- AU
- Piotroski score
- 3 / 9 (Weak)
- Altman Z-score
- -3.75
Financials
Revenue
$0.00-100.0%Net Income
$-12.32MEBITDA
$-13.30MFree Cash Flow
$-9.07MEPS (diluted)
$-3.95Shares Outstanding (diluted)
3.12M+15964.8%Operating Expenses
$13.30MCash & Debt
$69.39MRevenue by Segment (annual)
$0.00Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $42.0K | $-20.70M | $-18.90 |
| 2024 | $2.31M | $-26.78M | $-55.00 |
| 2023 | $555.00 | $-20.47M | $-55.00 |
| 2022 | $10.0K | $-25.01M | $-95.00 |
| 2021 | $15.18M | $-8.42M | $-35.80 |
| 2020 | $988.1K | $-12.47M | $-80.00 |
| 2019 | $1.6K | $-10.27M | $-85.60 |
| 2018 | $13.1K | $-6.04M | $-59.80 |
| 2017 | $8.79M | $-10.67M | $-109.30 |
| 2016 | $4.07M | $-12.06M | $-135.20 |
| 2015 | $89.0K | $-7.14M | $-143.45 |
| 2014 | $87.0K | $-7.47M | $-226.25 |
| 2013 | $1.07M | $-1.03M | $-42.70 |
| 2012 | $2.45M | $1.31M | $64.15 |
Valuation
KZIAhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
50-66.67%Social Signal Score
Mentions (9)
- Newsprnewswire.com·19d ago·Neutral
… Expands Development of Paxalisib Beyond Oncology and Triggers $2 Million Payment to Kazia SYDNEY, Sept. 22, 2026 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA), an oncology-focused biotechnology company developing therapies that selectively reprogram cancer biology, restore anti-tumor immunity and overcome treatment resistance, today announced that Sovargen Co., Ltd.
View source ↗ - Newsprnewswire.com·32d ago·Neutral
…ung adults with recurrent or progressive AT/RT, where no approved therapies currently exist SYDNEY, Sept. 9, 2026 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA) ("Kazia" or the "Company"), an oncology-focused biotechnology company developing therapies that selectively reprogram cancer biology, restore anti-tumor immunity and overcome treatment resistance, today announced that the first patient has been dosed in Arm A of PNOC035, a Phase 2 platform study evaluating paxalisib in combina…
View source ↗ - Newsseekingalpha.com·37d ago·Positive
Kazia Therapeutics Limited (KZIA) Discusses Clinical and Corporate Updates With Focus on Paxalisib Programs in Breast and Colorectal Cancer Transcript Kazia Therapeutics Limited (KZIA) Discusses Clinical and Corporate Updates With Focus on Paxalisib Programs in Breast and Colorectal Cancer Transcript
View source ↗ - Newsprnewswire.com·40d ago·Positive
…Standard-of-Care First Patient Expected By Year-End 2026 and Full Enrollment by End of 2027 SYDNEY, Sept. 1, 2026 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA) ("Kazia" or the "Company"), an oncology-focused biotechnology company developing therapies that selectively reprogram cancer biology, restore anti-tumor immunity and overcome treatment resistance, today announced new preclinical data demonstrating the safety and anti-tumor activity of paxalisib in HR+/HER2- breast cancer, incl…
View source ↗ - Newsprnewswire.com·41d ago·Neutral
…Public Offering Company to host a corporate update call Tuesday, September 1st at 8:00am ET SYDNEY, Aug. 31, 2026 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA) ("Kazia" or the "Company"), an oncology-focused biotechnology company developing therapies that selectively reprogram cancer biology, restore anti-tumor immunity and overcome treatment resistance, today announced the closing of its previously announced oversubscribed, tranched registered public offering (the "Offering") genera…
View source ↗ - Newsseekingalpha.com·41d ago·Neutral
Kazia Therapeutics: Worth Speculating On Paxalisib's TNBC Data Kazia's first 6 TNBC patients all achieved clinical benefits. These early results make paxalisib a much more promising asset going forward. Responses across visceral, skeletal, and CNS metastases make that early signal more compelling. But it's a relatively small and uncontrolled cohort. KZIA is working towards an expanded Phase 1b trial with 36 patients. That should give us a clearer picture about paxalisib's potential.
View source ↗ - Newsprnewswire.com·44d ago·Neutral
Kazia Therapeutics Limited Announces Pricing of Up to $120 Million Public Offering SYDNEY, Aug. 28, 2026 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA) ("Kazia" or the "Company"), an oncology-focused biotechnology company developing therapies that selectively reprogram cancer biology, restore anti-tumor immunity and overcome treatment resistance, today announced the pricing of its previously announced tranched registered public offering (the "Offering") of (i) 2,580,000 American Depos…
View source ↗ - Newsprnewswire.com·45d ago·Neutral
Kazia Therapeutics Limited Announces Proposed Public Offering SYDNEY, Aug. 27, 2026 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA) ("Kazia" or the "Company"), an oncology-focused biotechnology company developing therapies that selectively reprogram cancer biology, restore anti-tumor immunity and overcome treatment resistance, today announced that it has commenced a tranched registered public offering (the "Offering") of (i) American Depositary Shares ("ADSs"), each representing five h…
View source ↗ - Newsprnewswire.com·45d ago·Neutral
…Reductions of 83% and 51% Respectively No Treatment-Related Serious Adverse Events Observed SYDNEY, Aug. 27, 2026 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA) ("Kazia" or the "Company"), an oncology-focused biotechnology company developing therapies that selectively reprogram cancer biology, restore anti-tumor immunity and overcome treatment resistance, today announced new data showing its lead asset, paxalisib, achieved a 100% clinical benefit rate in six evaluable patients with St…
View source ↗
Earnings
Tue, Mar 2(in 5 months)
Consensus estimate $-0.45 per share
Typical surprise +32.8% (median, so one quarter with a near-zero estimate can't distort it)
- Fri, Sep 4$-0.60 vs $-0.61beat
- Mon, Mar 16$-0.58 vs $-0.01miss
- Fri, Nov 7$-0.43 vs $-0.01miss
- Tue, Jun 10$-3.81 vs $-10.76beat
- Thu, Feb 20$-20.80 vs $-15.00miss
- Mon, Sep 16$-0.30 vs $-3.00beat
Estimates and results for KZIA via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by KZIA officers and directors.
- Bought
- $13.1m
- Sold
- $1.5m
55 trades
13 trades
- Austin Josiah Tsold
- Austin Josiah Tsold
- Austin Josiah Tsold
- Austin Josiah Tsold
- Austin Josiah Tsold
- Austin Josiah Tsold
- Austin Josiah Tsold
- Austin Josiah Tsold
32 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in KZIA.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.